Seer, Inc. (SEER) - 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Seer, Inc.
Reporting Period: Fiscal year ended December 31, 2024.
Business Overview: Seer is a life sciences technology company developing the Proteograph Product Suite, an integrated solution (consumables, automation instrument, and software) designed to enable unbiased, deep, and large-scale proteomic analysis. The company leverages proprietary engineered nanoparticle technology to capture protein variants at the peptide level. As of December 31, 2024, Seer had 134 employees and serves over 135 customers in more than 20 countries. The company is classified as a smaller reporting company and a non-accelerated filer.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $14.2 million | $16.7 million |
| Gross Profit | $7.1 million | $8.5 million |
| Gross Margin | 49.8% | 51.1% |
| Net Loss | $(86.6) million | $(86.3) million |
| Operating Loss | $(100.1) million | $(103.5) million |
| Cash Used in Operating Activities | $(46.1) million | $(59.1) million |
| Cash, Cash Equivalents, and Investments | $299.5 million | $369.8 million |
| Accumulated Deficit | $(392.4) million | $(305.8) million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 15% ($2.5 million) year-over-year. This was primarily driven by a 51% decrease in related party revenue (largely from PrognomiQ) and an 85% decrease in grant and other revenue. Service revenue increased by 47%, partially offsetting the decline.
- Cost Reductions: Cost of revenue decreased by 13% ($1.0 million), largely due to fewer instrument sales which carry higher costs. Operating expenses decreased by 4% ($4.8 million), with reductions in Research & Development (5%) and Selling, General & Administrative (4%) expenses driven by lower headcount and reduced stock-based compensation.
- Stock Repurchases: The company repurchased approximately 6.47 million shares of Class A common stock under its share repurchase program during 2024, costing approximately $11.8 million. As of year-end, $13.2 million remained available under the program.
- Investment Activity: The company recognized a $2.6 million loss on its equity method investment in PrognomiQ, Inc., following a $10.0 million purchase of PrognomiQ Series D Preferred Stock in August 2024.
Guidance, Outlook, and Risks
Management Commentary & Outlook: Seer expects to continue incurring significant losses and does not anticipate positive cash flows from operations in the foreseeable future. Management believes current cash, cash equivalents, and investments ($299.5 million) are sufficient to fund operations for at least the next 12 months. The company is focused on broadening commercialization of the Proteograph Product Suite, expanding its installed base, and increasing service revenue through its Seer Technology Access Center (STAC). A new co-marketing and sales agreement with Thermo Fisher Scientific was announced in November 2024, expected to operationalize in early 2025.
Key Risks and Contingencies:
- Profitability: The company has a history of net losses and an accumulated deficit of $392.4 million. There is no assurance it will achieve or sustain profitability.
- Customer Concentration: PrognomiQ, a related party, accounted for 17% of total revenue in 2024 (down from 28% in 2023).
- Regulatory Uncertainty: While products are currently labeled "Research Use Only" (RUO), future expansion into clinical diagnostics could subject the company to FDA regulation, requiring costly and time-consuming approvals.
- Intellectual Property: The company relies on licensed patents from Brigham and Women's Hospital. Challenges to these patents or the inability to enforce them could impair commercialization.
- Supply Chain: The company relies on a single contract manufacturer (Hamilton Company) for its SP100 automation instrument.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $299.5 million cash position against projected burn rates, given the expectation of continued net losses.
- Related Party Dependence: Assess the sustainability of revenue streams given the significant drop in related party revenue from PrognomiQ and the company's 25% equity stake in that entity.
- Commercialization Progress: Monitor the impact of the new Thermo Fisher Scientific partnership and the expansion of the STAC service model on non-related party revenue growth.
- Stock-Based Compensation: Review the impact of the October 2024 option repricing on future compensation expenses and potential dilution.
- Regulatory Path: Evaluate the risks associated with the "Research Use Only" designation and the potential costs of transitioning to clinical diagnostic products.